stoxline Quote Chart Rank Option Currency Glossary
  
Revolution Medicines, Inc. (RVMD)
36.955  0.395 (1.08%)    04-22 15:25
Open: 37.13
High: 37.655
Volume: 731,335
  
Pre. Close: 36.56
Low: 36.5
Market Cap: 6,870(M)
Technical analysis
2025-04-22 2:50:06 PM
Short term     
Mid term     
Targets 6-month :  46.24 1-year :  54
Resists First :  39.59 Second :  46.24
Pivot price 34.59
Supports First :  33.15 Second :  29.17
MAs MA(5) :  36.59 MA(20) :  35.29
MA(100) :  41.46 MA(250) :  43.11
MACD MACD :  -0.5 Signal :  -1
%K %D K(14,3) :  87.1 D(3) :  81.5
RSI RSI(14): 53.3
52-week High :  62.4 Low :  29.17
Price, MAs and Bollinger Bands

Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.
[ RVMD ] has closed below upper band by 19.0%. Bollinger Bands are 15.5% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 37.92 - 38.1 38.1 - 38.28
Low: 35.48 - 35.71 35.71 - 35.93
Close: 36.14 - 36.5 36.5 - 36.86
Company Description

Revolution Medicines, Inc., a clinical-stage precision oncology company, focuses on developing therapies to inhibit frontier targets in RAS-addicted cancers. The company is developing RMC-4630, an inhibitor of SHP2, which is in Phase 1/2 clinical trial for the treatment of solid tumors, such as gynecologic and colorectal cancer tumors. It also develops RMC-5845, a selective inhibitor of SOS1, a protein that converts RAS (OFF) to RAS (ON) in cells; and RMC-5552, a hyperactivated selective inhibitor of mTORC1 signaling in tumors. In addition, the company is developing RMC-6291, a mutant-selective inhibitor of KRASG12C(ON) and NRASG12C(ON); and RMC-6236, a RAS-selective inhibitor of multiple RAS(ON) variants. Further, it develops RAS(ON) Inhibitors targeting KRASG13C(ON) and KRASG12D(ON). The company has a collaboration agreement with Sanofi for the research and development of SHP2 inhibitors, including RMC-4630. Revolution Medicines, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.

Headline News

Sun, 20 Apr 2025
Revolution Medicines to Participate in April 2025 Investor Conferences - GlobeNewswire

Tue, 01 Apr 2025
Revolution Medicines to Deliver Multiple Presentations at the 2025 American Association for Cancer Research (AACR) Annual Meeting - Yahoo Finance

Mon, 31 Mar 2025
Revolution Medicines to Participate in April 2025 Investor Conferences - GlobeNewswire

Mon, 31 Mar 2025
Revolution Medicines Brings Groundbreaking RAS Cancer Research to Major Healthcare Forums - Stock Titan

Sun, 30 Mar 2025
Is Revolution Medicines (RVMD) the Best Mid Cap Biotech Stock to Buy? - Yahoo Finance

Thu, 06 Mar 2025
Is Revolution Medicines, Inc. (RVMD) Among Stocks With At Least $20 Million In Insider Spending Recently? - Yahoo Finance

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Underperform
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Underperform
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Neutral
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Underperform
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Underperform
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Underperform
Stock Basics & Statistics
Exchange:
NASDAQ
Sector:
Healthcare
Industry:
Biotechnology
Shares Out 186 (M)
Shares Float 168 (M)
Held by Insiders 2 (%)
Held by Institutions 106.3 (%)
Shares Short 16,650 (K)
Shares Short P.Month 14,920 (K)
Stock Financials
EPS -3.58
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 12.18
Profit Margin 0 %
Operating Margin 0 %
Return on Assets (ttm) -18.7 %
Return on Equity (ttm) -29.4 %
Qtrly Rev. Growth 0 %
Gross Profit (p.s.) -3.19
Sales Per Share 0
EBITDA (p.s.) -3.68
Qtrly Earnings Growth 0 %
Operating Cash Flow -557 (M)
Levered Free Cash Flow -348 (M)
Stock Valuations
PE Ratio -10.38
PEG Ratio 0
Price to Book value 3.04
Price to Sales 0
Price to Cash Flow -12.39
Stock Dividends
Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android